Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/103904
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMarques, Joana-
dc.contributor.authorValle Delgado, Juan José-
dc.contributor.authorUrbán, Patricia-
dc.contributor.authorBaró, Elisabet-
dc.contributor.authorProhens López, Rafael-
dc.contributor.authorMayor Aparicio, Alfredo Gabriel-
dc.contributor.authorCisteró, Pau-
dc.contributor.authorDelves, Michael-
dc.contributor.authorSinden, Robert E.-
dc.contributor.authorGrandfils, Christian-
dc.contributor.authorPaz, José L. de-
dc.contributor.authorGarcía Salcedo, José A.-
dc.contributor.authorFernàndez Busquets, Xavier-
dc.date.accessioned2016-11-18T11:56:04Z-
dc.date.available2016-11-18T11:56:04Z-
dc.date.issued2016-10-05-
dc.identifier.issn1549-9634-
dc.identifier.urihttp://hdl.handle.net/2445/103904-
dc.description.abstractThe adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drugs, targeting molecules, or encapsulating structures is a strategy that can provide new nanotechnology-based, cost-efficient therapies against malaria. We have explored the modification of different liposome prototypes that had been developed in our group for the targeted delivery of antimalarial drugs to Plasmodium-infected red blood cells (pRBCs). These new models include: (i) immunoliposome-mediated release of new lipid-based antimalarials; (ii) liposomes targeted to pRBCs with covalently linked heparin to reduce anticoagulation risks; (iii) adaptation of heparin to pRBC targeting of chitosan nanoparticles; (iv) use of heparin for the targeting of Plasmodium stages in the mosquito vector; and (v) use of the non-anticoagulant glycosaminoglycan chondroitin 4-sulfate as a heparin surrogate for pRBC targeting. The results presented indicate that the tuning of existing nanovessels to new malaria-related targets is a valid low-cost alternative to the de novo development of targeted nanosystems.-
dc.format.extent12 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherElsevier-
dc.relation.isformatofVersió postprint del document publicat a: http://dx.doi.org/10.1016/j.nano.2016.09.010-
dc.relation.ispartofNanomedicine: Nanotechnology, Biology, and Medicine, 2016-
dc.relation.urihttp://dx.doi.org/10.1016/j.nano.2016.09.010-
dc.rightscc by (c) Marques et al., 2016-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/-
dc.subject.classificationNanomedicina-
dc.subject.classificationMalària-
dc.subject.otherNanomedicine-
dc.subject.otherMalaria-
dc.titleAdaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/acceptedVersion-
dc.date.updated2016-11-16T19:00:38Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (ISGlobal)
Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC))
Articles publicats en revistes (Institut de Nanociència i Nanotecnologia (IN2UB))

Files in This Item:
File Description SizeFormat 
marques2016_2277.pdf1.52 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons